Table 4.
Potential side effects of NASG treatment, by phase (N = 433).
| Pre (N = 225) | Post (N = 208) | RR and 95% CI | |
|---|---|---|---|
| Any side effects, % (n) | 64.4% (145) | 67.8% (141) | RR = 1.05 |
| 95% CI = 0.92–1.20 | |||
| Respiratory symptoms/dyspnoea, % (n) | 7.1% (16) | 8.2% (17) | RR = 1.15 |
| 95% CI = 0.60–2.22 | |||
| Reduced urine output, % (n) | 9.8% (22) | 10.1% (21) | RR = 1.03 |
| 95% CI = 0.59–1.82 | |||
| Nausea, % (n) | 28.0% (63) | 19.2% (40) | RR = 0.69 |
| 95% CI = 0.48–0.97 | |||
| Vomiting, % (n) | 29.3% (66) | 19.7% (41) | RR = 0.67 |
| 95% CI = 0.48–0.95 | |||
| Abdominal pain, % (n) | 60.9% (137) | 60.6% (126) | RR = 0.99 |
| 95% CI = 0.85–1.16 |